Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of FOLFOX6m plus monoclonal antibody with or without irinotecan hepatic chemoembolization for liver-limited metastatic colorectal cancer
2020-003795-40Phase 2Active
- Sponsor
- GEMCAD
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, oxaliplatin, fluorouracil, folinic acid, bevacizumab and 2 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by GEMCAD. Primary endpoint: Objective radiological response rate at 6 months. Started Sep 2024; status: active.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acidbevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-003795-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003795-40.